Study: Conservative Treatment Normalizes Head Shape in Most Infants with Skull Flattening
Helmet Therapy Is Still Effective When Needed for Positional Cranial Deformity, Reports Plastic and Reconstructive Surgery
More than three-fourths of infants with skull flattening related to sleep position achieve normal head shape with conservative treatment—without the need for helmet therapy, reports a study in the March issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
With the addition of helmet therapy for infants with persistent skull flattening, multidisciplinary treatment for positional cranial deformity (PCD) has a success rate of over 90 percent, according to the new research by ASPS Member Surgeon Frank A. Vicari, MD, and colleagues of Ann and Robert H. Lurie Children's Hospital of Chicago. The largest study of PCD treatment to date, the results show the effectiveness of both conservative and helmet therapy, as confirmed by objective measurements.
Treatment for PCD—Outcomes in More Than 4,000 Infants
Dr. Vicari and colleagues analyzed their experience with 4,378 infants with flattening of one side of the head (plagiocephaly) or of the back of the head (brachycephaly). These problems occur when the baby always sleeps in the same position, causing pressure on the same spot on the skull.
Positional skull deformities have become more common since the recommendation to place babies on their backs to sleep. The "Back to Sleep" campaign (now called "Safe to Sleep") has been highly effective in lowering nationwide rates of sudden infant death syndrome (SIDS).
The researchers compared final skull shape for nearly 3,000 infants initially receiving conservative therapy for PCD and nearly 1,000 infants receiving helmet therapy. Conservative treatment consists of advice and/or physical therapy, including steps to keep the baby from lying in the same position all the time and to encourage daily "tummy time" when the baby is awake.
Helmet therapy consists of a custom-made orthosis to help shape the developing skull. Treatments weren't randomly assigned—rather, the decision was made by a pediatric plastic surgeon after thorough assessment by a multidisciplinary treatment team, with strong consideration of parent preferences. Final skull shape was objectively measured using 3D laser surface scanning.
Conservative treatment normalized skull shape in 77 percent of infants. About 16 percent of infants initially assigned to conservative treatment were switched to helmet therapy. The remaining seven percent had "incomplete correction" of skull flattening.
If Conservative Treatment Fails, Helmets Are Still Effective
For infants initially treated with helmet therapy, the rate of complete correction was 94 percent. The success rate was also very high—96 percent—in approximately 500 infants who were switched to helmet therapy who didn't improve after a few months of conservative treatment. "In the majority of infants, delaying helmet therapy for a trial of conservative treatment does not preclude the achievement of complete correction," Dr. Vicari and coauthors write.
The study identified some key risk factors for failed treatment of PCD. For both conservative and helmet therapy, failure rates were higher for parents with "poor compliance"—who didn't follow advice regarding repositioning or helmet wear. Risk was also higher for infants with more severe deformities, older age when starting treatment, and the presence of congenital torticollis (a condition in which the head is tilted to one side).
In a special expert commentary video on the Plastic and Reconstructive Surgery website, Dr. Kant Lin emphasizes that the study does not make "any conclusive statement about the superiority of one treatment method over the other." Rather, he states, "This information can be used to help pediatricians to reassure parents about the likelihood of a completely successful treatment of their child's skull deformity." Dr. Lin also comments that infants with PCD "are best evaluated by a multidisciplinary trained team of surgeons, nurses, physical therapists, and orthotists."
Plastic and Reconstructive Surgery® is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health.
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.